Stereotactic body radiotherapy for lung XXXX as oligo-recurrence: a single institutional study.

@entity1 @entity137 @entity55 @entity5 @entity14 @entity3
UNASSIGNED: The purpose of this study was to investigate clinical outcomes following stereotactic body radiotherapy (SBRT) for lung @entity3 as oligo-recurrence. From May 2003 to June 2014, records for 66 @entity1 with 76 oligo-recurrences in the lungs treated with SBRT were retrospectively reviewed. Oligo-recurrence primary sites and @entity1 numbers were as follows: lungs, 31; colorectal, 13; head and neck, 10; esophagus, 3; uterus, 3; and others, 6. The median SBRT dose was 50 Gy (range, 45-60 Gy) administered in a median of 5 (range, 5-9) fractions. All @entity1 received SBRT, with no acute @entity137 . Surviving @entity1 had a median follow-up time of 36.5 months. The 3-year rates of local control, overall survival and disease-free survival were 90.6%, 76.0% and 53.7%, respectively. Longer disease-free interval from initial treatment to SBRT, and @entity14 were both associated with favorable outcomes. Disease progression after SBRT occurred in 31 @entity1 , most with distant @entity3 (n = 24) [among whom, 87.5% (n = 21) had new lung @entity3 ]. Among these 21 @entity1 , 12 were judged as having a second oligo-recurrence. Additional SBRT was performed for these 12 @entity1 , and all 12 @entity5 were controlled without disease progression. Three @entity1 (4.5%) developed Grade 2 radiation @entity55 . No other late adverse events of Grade >= 2 were identified. Thus, SBRT for oligo-recurrence achieved acceptable @entity5 control, with additional SBRT also effective for selected @entity1 with a second oligo-recurrence after primary SBRT.
